Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease

被引：0
|
作者：
White, William B. [1 ]
Gunawardhana, Lhanoo [2 ]
机构：
[1] Univ Connecticut, Sch Med, Cardiol, Farmington, CT USA
[2] Takeda Pharmaceut Int, Deerfield, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2242
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol?
    W Winn Chatham
    Kenneth G Saag
    Nature Clinical Practice Rheumatology, 2006, 2 (5): : 240 - 241
  • [32] Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
    Zhang, Shengzhao
    Xu, Ting
    Shi, Qingyang
    Li, Sheyu
    Wang, Ling
    An, Zhenmei
    Su, Na
    FRONTIERS IN MEDICINE, 2021, 8
  • [33] Febuxostat Leads to Better Cardiovascular Outcomes Compared to Allopurinol in Patients With Advanced Chronic Kidney Disease: A Population-Based Cohort Study
    Tsai, Ming-Hsien
    Chen, Yun-Yi
    Liou, Hung-Hsiang
    Wang, Jing-Tong
    Fang, Yu-Wei
    AMERICAN JOURNAL OF MEDICINE, 2025, 138 (02):
  • [34] Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
    Tsuruta, Yuki
    Mochizuki, Toshio
    Moriyama, Takahito
    Itabashi, Mitsuyo
    Takei, Takashi
    Tsuchiya, Ken
    Nitta, Kosaku
    CLINICAL RHEUMATOLOGY, 2014, 33 (11) : 1643 - 1648
  • [35] Outcome Of Allopurinol Or Febuxostat Treatment In Gout Patients Naive To Urate-Lowering Therapy
    Khanna, Puja
    Hatoum, Hind
    Lin, Swu-Jane
    Shiozawa, Aki
    Akhras, Kasem
    Khanna, Dinesh
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S857 - S857
  • [36] Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
    Liao, Zhimin
    Xu, Lei
    Wan, Bo
    Wang, Liping
    Zhao, Chengzhi
    Wu, Gang
    Xie, Rui
    EMERGENCY MEDICINE INTERNATIONAL, 2022, 2022
  • [37] Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
    Yuki Tsuruta
    Toshio Mochizuki
    Takahito Moriyama
    Mitsuyo Itabashi
    Takashi Takei
    Ken Tsuchiya
    Kosaku Nitta
    Clinical Rheumatology, 2014, 33 : 1643 - 1648
  • [38] Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
    Peng, Yueh-Lung
    Tain, You-Lin
    Lee, Chien-Te
    Yang, Yi-Hsn
    Huang, Yaw-Bin
    Wen, Yen-Hsia
    Hsu, Chien-Ning
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [39] Febuxostat was Better than Allopurinol in Patients with Advanced Chronic Kidney Disease
    Hao, Zhen-Ye
    Qiao, Peng-Yan
    Wei, James Cheng-Chung
    Zhang, Li-Yun
    AMERICAN JOURNAL OF MEDICINE, 2025, 138 (04): : e68 - e68
  • [40] Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis"
    Gao, Linggen
    Wang, Bin
    Cheng, Rui
    CLINICAL CARDIOLOGY, 2022, 45 (07) : 687 - 690
12345